S2Medical AB (S2M) - Total Assets
Based on the latest financial reports, S2Medical AB (S2M) holds total assets worth Skr16.78 Million SEK (≈ $1.81 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check S2M capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
S2Medical AB - Total Assets Trend (2015–2025)
This chart illustrates how S2Medical AB's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of S2Medical AB to evaluate the quality of earnings relative to operating cash generation.
S2Medical AB - Asset Composition Analysis
Current Asset Composition (December 2025)
S2Medical AB's total assets of Skr16.78 Million consist of 22.9% current assets and 77.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 5.4% |
| Accounts Receivable | Skr1.56 Million | 9.3% |
| Inventory | Skr1.37 Million | 8.2% |
| Property, Plant & Equipment | Skr202.00K | 1.2% |
| Intangible Assets | Skr12.55 Million | 74.8% |
| Goodwill | Skr189.00K | 1.1% |
Asset Composition Trend (2015–2025)
This chart illustrates how S2Medical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see S2Medical AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: S2Medical AB's current assets represent 22.9% of total assets in 2025, a decrease from 59.5% in 2015.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2025, down from 42.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 75.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 74.8% of total assets.
S2Medical AB Competitors by Total Assets
Key competitors of S2Medical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.68 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Tarsons Products Limited
NSE:TARSONS
|
India | Rs11.64 Billion |
|
SciVision Biotech Inc
TW:1786
|
Taiwan | NT$2.67 Billion |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
S2Medical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.92 | 3.79 |
| Quick Ratio | 0.36 | 0.86 | 3.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-3.06 Million | Skr-495.76K | Skr23.06 Million |
S2Medical AB - Advanced Valuation Insights
This section examines the relationship between S2Medical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | Skr16.78 Million |
| Market Capitalization | $502.89K USD |
Valuation Analysis
Below Book Valuation: The market values S2Medical AB's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: S2Medical AB's assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for S2Medical AB (2015–2025)
The table below shows the annual total assets of S2Medical AB from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr16.78 Million ≈ $1.81 Million |
-7.26% |
| 2024-12-31 | Skr18.09 Million ≈ $1.95 Million |
-15.50% |
| 2023-12-31 | Skr21.41 Million ≈ $2.30 Million |
-15.37% |
| 2022-12-31 | Skr25.29 Million ≈ $2.72 Million |
-14.77% |
| 2021-12-31 | Skr29.68 Million ≈ $3.19 Million |
-28.04% |
| 2020-12-31 | Skr41.24 Million ≈ $4.44 Million |
+34.29% |
| 2019-12-31 | Skr30.71 Million ≈ $3.31 Million |
-37.43% |
| 2018-12-31 | Skr49.08 Million ≈ $5.28 Million |
+339.28% |
| 2017-12-31 | Skr11.17 Million ≈ $1.20 Million |
+73.87% |
| 2016-12-31 | Skr6.43 Million ≈ $691.54K |
+83.86% |
| 2015-12-31 | Skr3.50 Million ≈ $376.12K |
-- |
About S2Medical AB
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and… Read more